🇺🇸 FDA

Intelligence · Clinical Pipeline

LIGAND PHARMACEUTICALS Pipeline

All ClinicalTrials.gov programs at LIGAND PHARMACEUTICALS — phase, modality, and trial IDs.

Programs
22

Quick answer

LIGAND PHARMACEUTICALS has 22 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Alitretinoin

    LIGAND PHARMACEUTICALS INC

    Sarcoma, Kaposi

    phase 2 small molecule completed

    2 trials

  2. Aplindore

    LIGAND PHARMACEUTICALS INC

    Early Stage Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  3. Aplindore

    LIGAND PHARMACEUTICALS INC

    Restless Legs Syndrome

    phase 2 small molecule completed

    1 trial

  4. Bexarotene

    LIGAND PHARMACEUTICALS INC

    Sarcoma, Kaposi

    phase 2 small molecule completed

    1 trial

  5. Bexarotene

    LIGAND PHARMACEUTICALS INC

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  6. Bexarotene (targretin)

    LIGAND PHARMACEUTICALS INC

    Carcinoma, Non-small-cell Lung

    phase 2 small molecule terminated

    1 trial

  7. Bexarotene 1% gel

    LIGAND PHARMACEUTICALS INC

    Parapsoriasis

    phase 2 small molecule terminated

    1 trial

  8. Bexarotene/NBUVB vs placebo NBUVB

    LIGAND PHARMACEUTICALS INC

    Psoriasis

    phase 2 small molecule completed

    1 trial

  9. Budesonide

    LIGAND PHARMACEUTICALS INC

    Seasonal Allergic Rhinitis

    phase 2 small molecule completed

    1 trial

  10. Budesonide + Azelastine

    LIGAND PHARMACEUTICALS INC

    Seasonal Allergic Rhinitis

    phase 2 small molecule completed

    1 trial

  11. CE-Iohexol

    LIGAND PHARMACEUTICALS INC

    Contrast-induced Nephropathy

    phase 2 small molecule terminated

    1 trial

  12. LGD-6972-5 mg

    LIGAND PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  13. Lasofoxifene

    LIGAND PHARMACEUTICALS INC

    Bone Loss

    phase 2 small molecule completed

    1 trial

  14. MB07133 300mg/m2/day

    LIGAND PHARMACEUTICALS INC

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  15. MB07803

    LIGAND PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  16. MB07811

    LIGAND PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 2 small molecule terminated

    1 trial

  17. PS433540

    LIGAND PHARMACEUTICALS INC

    Hypertension

    phase 2 small molecule completed

    1 trial

  18. bexarotene

    LIGAND PHARMACEUTICALS INC

    Cutaneous T-Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  19. bexarotene

    LIGAND PHARMACEUTICALS INC

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  20. denileukin diftitox

    LIGAND PHARMACEUTICALS INC

    Drug/Agent Toxicity by Tissue/Organ

    phase 2 mab completed

    1 trial

  21. erlotinib and bexarotene

    LIGAND PHARMACEUTICALS INC

    Carcinoma, Non-small-cell Lung

    phase 2 small molecule completed

    1 trial

  22. irbesartan

    LIGAND PHARMACEUTICALS INC

    Hypertension

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does LIGAND PHARMACEUTICALS have?

22 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.